We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw

By LabMedica International staff writers
Posted on 16 Oct 2023

One of the toughest challenges for cancer patients undergoing chemotherapy is experiencing a low count of white blood cells, also known as neutropenia. More...

These cells play a crucial role in warding off infections. A low count leaves patients, who are already vulnerable due to cancer, susceptible to other diseases. Furthermore, if the white blood cell count drops too much, it can become risky to proceed with additional chemotherapy sessions. Monitoring these cell levels is therefore critical for patient care. Now, a new portable device allows patients to monitor their white blood cell counts from the comfort of their homes, without needing to draw blood. This is a game-changer as it enables more frequent testing for millions of patients with compromised immune systems, ultimately improving their clinical results and quality of life.

Leuko Labs Inc. (Boston, MA, USA) is developing PointCheck, the first-of-its-kind device that noninvasively screens for severe neutropenia. The device works by imaging blood as it flows through the capillaries in the finger, enabling it to determine whether white blood cell levels have reached critically low points, all without the need for a blood sample. Designed for home use, the finger-based test involves shining light onto the skin near the fingernail to capture images of blood cells in the surface-level capillaries. The device then uses Leuko Labs' specialized AI algorithms to assess whether the white blood cell count is dangerously low in just one minute.

The key benefit of PointCheck lies in its ability to flag elevated infection risks, thus prompting timely preventive treatments before an actual infection takes hold. Detecting severely low levels of neutrophils—a common subtype of white blood cells—early and continuous monitoring can prevent serious infections such as febrile neutropenia. Because PointCheck is noninvasive and quick, it empowers patients to monitor their own neutrophil levels at home, facilitating timely and effective treatment.

Related Links:
Leuko Labs Inc.


Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
Rapid Sepsis Test
SeptiCyte RAPID
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.